| Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. WJ Connors, Joseph M New England Journal of Medicine 378, 331-344, 2018 | 787 | 2018 |
| Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT3 receptor … P Eisenberg, J Figueroa‐Vadillo, R Zamora, V Charu, J Hajdenberg, ... Cancer 98 (11), 2473-2482, 2003 | 531 | 2003 |
| Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America WM Stadler, RA Figlin, DF McDermott, JP Dutcher, JJ Knox, WH Miller Jr, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2010 | 300 | 2010 |
| Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non–germinal center B-cell–like diffuse large B-cell lymphoma JP Leonard, KS Kolibaba, JA Reeves, A Tulpule, IW Flinn, T Kolevska, ... Journal of Clinical Oncology 35 (31), 3538-3546, 2017 | 182 | 2017 |
| Pheochromocytoma of the urinary bladder: a systematic review of the contemporary literature JA Beilan, A Lawton, J Hajdenberg, CJ Rosser BMC urology 13, 1-6, 2013 | 169 | 2013 |
| Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. T Grote, J Hajdenberg, A Cartmell, S Ferguson, A Ginkel, V Charu The journal of supportive oncology 4 (8), 403-408, 2006 | 111 | 2006 |
| Sacituzumab govitecan, a novel antibody–drug conjugate, in patients with metastatic platinum-resistant urothelial carcinoma B Faltas, DM Goldenberg, AJ Ocean, SV Govindan, F Wilhelm, ... Clinical Genitourinary Cancer 14 (1), e75-e79, 2016 | 108 | 2016 |
| Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study. ST Tagawa, BM Faltas, ET Lam, PJ Saylor, A Bardia, J Hajdenberg, ... Journal of Clinical Oncology 37 (7_suppl), 354-354, 2019 | 89 | 2019 |
| Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program RM Bukowski, WM Stadler, DF McDermott, JP Dutcher, JJ Knox, ... Oncology 78 (5-6), 340-347, 2010 | 51 | 2010 |
| Single Agent dabrafenib for BRAFV600E mutated histiocytosis DEL Bhatia, A., Ulaner G, Rampal, R. Hyman DM, Abdel-Wahab O, Durham BH ... Haematologica, 2018 | 48 | 2018 |
| A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors DR Feldman, LH Einhorn, DI Quinn, Y Loriot, JK Joffe, DJ Vaughn, ... Investigational new drugs 31, 1016-1022, 2013 | 47 | 2013 |
| Randomized phase 2 open-label study of R-CHOP±bortezomib in patients (Pts) with untreated non-germinal center B-cell-like (non-GCB) subtype diffuse large cell lymphoma (DLBCL … JP Leonard, K Kolibaba, JA Reeves, A Tulpule, IW Flinn, T Kolevska, ... Blood 126 (23), 811, 2015 | 35 | 2015 |
| 99-04 Palonosetron Study Group Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor … P Eisenberg, J Figueroa-Vadillo, R Zamora, V Charu, J Hajdenberg, ... Cancer 98 (11), 2473-82, 2003 | 33 | 2003 |
| Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting. J Hajdenberg, T Grote, L Yee, R Arevalo-Araujo, LA Latimer The journal of supportive oncology 4 (9), 467-471, 2006 | 32 | 2006 |
| Sacituzumab govitecan (IMMU-132) for patients with pretreated metastatic urothelial uancer (UC): interim results ST Tagawa, B Faltas, E Lam, P Saylor, A Bardia, J Hajdenberg, ... Annals of Oncology 28, v301-v302, 2017 | 30 | 2017 |
| The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial: safety and efficacy in patients (pts) with prior bevacizumab (BEV) treatment HA Drabkin, RA Figlin, WM Stadler, TE Hutson, J Hajdenberg, L Chu, ... Journal of Clinical Oncology 25 (18_suppl), 5041-5041, 2007 | 30 | 2007 |
| Locally advanced paraganglioma of the urinary bladder: a case report J Beilan, A Lawton, J Hajdenberg, CJ Rosser BMC Research Notes 6, 1-4, 2013 | 17 | 2013 |
| Palonosetron is active in preventing acute and delayed emesis following moderately emetogenic chemotherapy: results of a phase III trial SM Grunberg, J Hajdenberg, V Charu Support Care Cancer 10, 2002 | 15 | 2002 |
| Lifestyle interventions in the prevention and treatment of cancer CH Brown, SM Baidas, JJ Hajdenberg, OR Kayaleh, GK Pennock, ... American Journal of Lifestyle Medicine 3 (5), 337-348, 2009 | 13 | 2009 |
| A Phase II trial of Thymitaq™(AG337) in patients with hepatocellular carcinoma KE Stuart, J Hajdenberg, A Cohn, KK Loh, W Miller, C White, ... Proc ASCO 15, 202, 1996 | 12 | 1996 |
